title: Small molecules targeting JAKs--a new approach in the treatment of rheumatoid arthritis.
abstract: Advances in the treatment of RA in the past decade have been achieved mainly by using combinations of different conventional and biologic DMARDs. However, until now no final victory has been achieved over this organ damaging and potentially life-threatening systemic autoimmune disease. Few patients, notably those with established disease, stay in remission permanently, even using advanced treatment concepts. Thus novel approaches, especially for patients resistant to biologics, are urgently needed. Pro-inflammatory signalling pathways beyond the level of cytokines and receptors have been intensively elaborated and provide such potential targets. This review focuses on the development of new small molecule inhibitors of Janus kinases in clinical trials in RA.
authors: Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Charitéplatz 1, D-10117 Berlin, Germany. eugen.feist@charite.de
authors: Eugen
authors: E
authors: Feist
authors: Gerd R
authors: GR
authors: Burmester
mesh_terms: D000284:Administration, Oral; D000631:Aminopyridines; D018501:Antirheumatic Agents / Q000008:administration & dosage; D001172:Arthritis, Rheumatoid / Q000175:diagnosis* / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005544:Forecasting; D005858:Germany; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors*; D008297:Male; D020714:Maximum Tolerated Dose; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends*; D009025:Morpholines; D010078:Oxazines / Q000008:administration & dosage; D010880:Piperidines / Q000008:administration & dosage*; D011379:Prognosis; D011725:Pyridines / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage*; D011758:Pyrroles / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000631:Aminopyridines; D018501:Antirheumatic Agents; D009025:Morpholines; D010078:Oxazines; D010880:Piperidines; D011725:Pyridines; D011743:Pyrimidines; D011758:Pyrroles; C479163:tofacitinib; D053612:Janus Kinases; C523665:fostamatinib
keywords: fostamatinib; janus kinase; rheumatoid arthritis; tofacitinib